Repare Therapeutics Stock News

Repare Therapeutics Inc. (NASDAQ:RPTX) Director Thomas Civik acquired 7,500 shares of the firms stock in a transaction on Tuesday, November 16th. The shares were acquired at an average price of $28.08 per share, with a total value of $210,600.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is []

Related Stocks: RPTX ,

Repare Therapeutics (NASDAQ:RPTX) had its target price lifted by equities researchers at Northland Securities from $40.00 to $45.00 in a research report issued on Thursday, The Fly reports. The brokerage presently has an outperform rating on the stock. Northland Securities price objective indicates a potential upside of 66.24% from the companys previous close. Several other []

The shares of Repare Therapeutics Inc (NASDAQ: RPTX) have received a price target of $48 from Stifel. These are the details.

Repare Therapeutics Inc. (RPTX) delivered earnings and revenue surprises of -18.57% and 39.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the

Repare Therapeutics Inc (NASDAQ: RPTX) announced the presentation of preliminary Phase 1 monotherapy data from its Phase 1/2 TRESR trial of RP-3500 for solid tumors with specific synthetic-lethal g

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the pres

The stock price of Repare Therapeutics Inc (NASDAQ: RPTX) increased by over 17% during intraday trading today. This is why it happened.

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today issued the followi

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietar

Should you follow Cathie Wood's latest genomic revolution investments?

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq:RPTX), a leading clinical-stage precision oncology company enabled by its proprietary

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietar

CAMBRIDGE, Mass. & MONTREAL, Quebec--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its pr

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietar